Therapy News and Research

RSS

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

UCSF receives $6.5 million gift from philanthropists Irwin and Joan Jacobs of La Jolla

Philanthropists Irwin and Joan Jacobs of La Jolla, CA are giving a $6.5 million gift to UCSF for head and neck cancer research. It is believed to be the largest private, U.S. gift for research supporting this disease.

28 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

URI scientists discover a new and effective approach for treating cancerous tumor

Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.

27 Oct 2009

BIOTRONIK launches its new, unified platform pacemaker series in Europe

BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the European launch of its new, unified platform pacemaker series, Evia, and several new products to further strengthen its bradycardia portfolio.

27 Oct 2009

NIH awards The Tufts CTSI and Tufts University four supplemental grants

The Tufts Clinical and Translational Science Institute (CTSI) and Tufts University today announced they are the recipients of four supplemental grant awards from the National Institutes of Health. These new awards, totaling approximately $1.73 million, are supplements to the original Clinical and Translational Science Award (CTSA) grant, UL1 RR025752 that Tufts University received in 2008 from the National Center for Research Resources.

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Interim results from FREEDOM study announced by NxStage Medical

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study. The FREEDOM data will be presented in posters at the American Society of Nephrology (ASN) Renal Week 2009, from October 27th to November 1st in San Diego.

27 Oct 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

New therapy for decreasing anxiety and improving psychological well-being in children

A group of investigators of the University of Bologna suggest a new way of approaching emotional disturbances in children by improving their psychological well-being. The study is published in the current issue of Psychotherapy and Psychosomatics.

27 Oct 2009

International experts discuss ion radiation therapy

The largest congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg. Well over 600 international participants, especially from Japan and the USA, convened in the Heidelberg Town Hall for the annual meeting of the "Particle Therapy Cooperative Group" (PTCOG), including leading experts from the fields of radiation therapy, medical physics and oncology.

27 Oct 2009

Adenosine deaminase enzyme therapy offers hope for priapism

For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. That's because researchers from the United States and China show that the enzyme adenosine deaminase may prevent priapism from progressing to penile fibrosis, a condition associated with the build up of scar tissue and eventual impotence.

27 Oct 2009

Study: Minimally invasive procedure reduces cost and complications compared to open surgery

Ethicon Endo-Surgery today announced results from two newly published studies that demonstrate a minimally invasive approach in three common procedures resulted in a reduced rate of complications and lower overall cost of care, including a difference of more than $15,000 on average for minimally invasive colectomies, when compared to open surgery.

27 Oct 2009

Bayshore Home Health acquires Nightingale Nursing Group

Bayshore Home Health announced today the purchase of Saskatoon-based home health care company Nightingale Nursing Group Inc. The acquisition expands Bayshore's presence in the province, complements its existing office in Regina, and provides an opportunity to service additional remote northern communities.

27 Oct 2009

GI Solutions to conduct new incision-free procedure for GERD patients

Chicago woman will be among the first in the country to undergo a new incision-less, endoscopic procedure that could get rid of Gastrointestinal Esophageal Reflux Disease (GERD) forever.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

BMC surgeons use new EsophyX TIF for treatment of acid reflux or GERD

Boston Medical Center (BMC) surgeons are now offering patients an incisionless alternative to laparoscopic and traditional surgery for treatment of acid reflux or GERD.

27 Oct 2009

Therapy News and Research

NCI grant to conduct innovative cancer research

UCSF receives $6.5 million gift from philanthropists Irwin and Joan Jacobs of La Jolla

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

URI scientists discover a new and effective approach for treating cancerous tumor

BIOTRONIK launches its new, unified platform pacemaker series in Europe

NIH awards The Tufts CTSI and Tufts University four supplemental grants

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Interim results from FREEDOM study announced by NxStage Medical

Positive results from Phase II clinical trial of INT-747 announced

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

New systematic study for managing treatment-resistant bipolar depression

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

New therapy for decreasing anxiety and improving psychological well-being in children

International experts discuss ion radiation therapy

Adenosine deaminase enzyme therapy offers hope for priapism

Study: Minimally invasive procedure reduces cost and complications compared to open surgery

Bayshore Home Health acquires Nightingale Nursing Group

GI Solutions to conduct new incision-free procedure for GERD patients

LX211 may become the first approved oral treatment for modifying the course of uveitis

BMC surgeons use new EsophyX TIF for treatment of acid reflux or GERD

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News